SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of August.
On August 16, 2023, at 2:00 p.m. PDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the UBS MedTech, Tools, and Genomics Summit 2023, being held at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California.
A live webcast of the presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events. An archived version of the webcast will also be available on the Maravai website following the completion of the event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
| Last Trade: | US$1.69 |
| Daily Change: | -0.04 -2.03 |
| Daily Volume: | 272,999 |
| Market Cap: | US$239.000M |
February 04, 2025 January 28, 2025 January 08, 2025 December 05, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
